The life sciences angle

BioTech, BioPharma, and MedTech firms are operating under intense pressure from investors demanding capital efficiency, from a fiercely competitive talent market for AI and data expertise, and from a regulatory environment (FDA, EMA, MDR, HIPAA) that is intensifying faster than most internal governance models can keep pace with.

AI decisions made today will define competitive positioning at launch making this conversation urgent, and not theoretical. The barrier is no longer technical but organizational will, structural design, and leadership accountability.

Held near Kendall Square—widely regarded as the most innovative square mile in the world and the premier global hub for the life sciences—this roundtable will explore some of the key considerations in becoming AI-ready, including:

• A tested governance playbook: A clear, peer-validated framework for assigning AI accountability including where to embed it in existing org structures vs. where to create something new.
• The investment conversation, reframed: Practical language and precedents for making the internal case for AI investment when ROI is still hard to quantify informed by peers who have already navigated this with their CFOs and boards.
• Clarity on build vs. partner: An honest benchmark of what AI capability must be owned in-house to remain competitive and what can be safely entrusted to an external partner without ceding strategic control.